Work

Bortezomib Maintenance (BM) Versus Consolidation (BC) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (ASCT) for Untreated Mantle Cell Lymphoma (MCL): CALGB (Alliance) 50403

Year: 2015

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood.v126.23.337.337

Authors: Lawrence D. Kaplan, Sin-Ho Jung, Wendy Stock, Nancy L. Bartlett, Brandelyn Pitcher, John C. Byrd, Kristie A. Blum, Ann S. LaCasce, Noreen Fulton, Eric D. Hsi, David D Hurd, Myron Czuczman, John P. Leonard, Bruce D. Cheson

Institutions: University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, Duke University, University of Chicago Medical Center, Washington University in St. Louis, Alvin J. Siteman Cancer Center, The Ohio State University, Dana-Farber Cancer Institute, Cleveland Clinic, Wake Forest University, Roswell Park Comprehensive Cancer Center, Weill Cornell Medicine, Georgetown University, Georgetown University Medical Center, Georgetown Lombardi Comprehensive Cancer Center

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2556491571

FWCI: 5.729

Cites:

Cited by: 30

Related to: 10